Clinical Trial Validates SugaRite™ Probiotic Ingredient for Metabolic Health and Glycemic Support Applications
Bioyitech Announces Human Clinical Evidence Supporting the Potential Application ofSugaRite™ Compound Lactic Acid Bacteria Powder in Metabolic Health Product Development
Bioyitech has released clinical trial results demonstrating the potential application of SugaRite™ compound lactic acid bacteria powder (ZC-SUGII) as a clinically evaluated probiotic ingredient for metabolic health product development.
A randomized, double-blind, placebo-controlled dietary intervention study showed that 90-day supplementation with SugaRite™ was associated with improvements in key metabolic health indicators, including glycated hemoglobin (HbA1c), fasting blood glucose, postprandial glucose response, insulin resistance-related markers, and insulin sensitivity parameters.
The findings provide scientific support for the development of probiotic-based solutions targeting glycemic health management, metabolic wellness, and functional nutrition applications.
Clinical Study Overview
The randomized, double-blind, placebo-controlled dietary trial enrolled 60 participants diagnosed with type 2 diabetes mellitus.
Participants were randomly assigned to receive either SugaRite™ supplementation or placebo under controlled trial conditions for 90 consecutive days.
Supplementation Protocol
- Ingredient: SugaRite™ Compound Lactic Acid Bacteria Powder (ZC-SUGII)
- Dosage: 2 g twice daily
- Study Duration: 90 days
Evaluated Clinical Indicators
The study assessed multiple glucose and metabolic-related parameters, including:
- Glycated hemoglobin (HbA1c)
- Fasting blood glucose
- 2-hour postprandial blood glucose
- Serum insulin levels
- C-peptide levels
- HOMA-IR insulin resistance index
- Other metabolic health biomarkers
Key Clinical Findings
| Clinical Indicator | Study Outcome |
|---|---|
| Study Duration | 90 days |
| Participants | 60 subjects with type 2 diabetes mellitus |
| Supplementation | 2 g SugaRite™ twice daily |
| HbA1c Improvement | Reduced from 7.14% to 6.42% after 90 days |
| Average HbA1c Reduction | 0.73% decrease |
| HbA1c Target Achievement | 80.95% of SugaRite™ group achieved HbA1c below 7.0% |
| Insulin Resistance Indicator | HOMA-IR index significantly improved (p=0.0433) |
SugaRite™ Supplementation Supports HbA1c Improvement
After 90 days of supplementation, participants receiving SugaRite™ showed improvements in long-term glycemic management indicators.
The average HbA1c level in the SugaRite™ group decreased from 7.14% at baseline to 6.42% after 90 days, representing an average reduction of 0.73%.
The improvement was greater compared with the placebo group, demonstrating a significant difference between the two groups.
In addition, 80.95% of participants in the SugaRite™ group achieved HbA1c levels below 7.0%, indicating positive changes in glycated hemoglobin levels during the intervention period.
Supports Blood Glucose Balance and Postprandial Response
The study also evaluated changes in daily glucose-related indicators, including fasting blood glucose and postprandial glucose response.
Throughout the intervention period, participants receiving SugaRite™ demonstrated improved glucose control performance compared with the placebo group.
At Day 60, the average 2-hour postprandial blood glucose level in the SugaRite™ group was 9.04 mmol/L, compared with 11.07 mmol/L in the placebo group.
These findings suggest that SugaRite™ may support improved post-meal glucose response and contribute to better daily glucose balance.
Supports Insulin Sensitivity and Metabolic Health
Insulin resistance is an important factor associated with metabolic imbalance.
During the study, participants supplemented with SugaRite™ showed improvements in insulin-related metabolic indicators.
From Day 60 onward, serum insulin and C-peptide levels in the SugaRite™ group were lower compared with the placebo group. Meanwhile, the HOMA-IR insulin resistance index showed a statistically significant improvement (p=0.0433).
These results suggest that SugaRite™ may support healthier insulin utilization and contribute to improved insulin sensitivity-related outcomes.
SugaRite™: A Clinically Evaluated Probiotic Ingredient for Metabolic Health Solutions
The 90-day human dietary trial provides scientific evidence supporting the potential use of SugaRite™ compound lactic acid bacteria powder in metabolic health applications.
As a Multi-Strain probiotic ingredient, SugaRite™ is suitable for manufacturers developing:
- Dietary Supplements
- Functional foods
- Probiotic formulations
- Metabolic health products
- Nutrition solutions targeting glycemic balance support
With clinically evaluated performance and advanced probiotic technology, SugaRite™ provides a reliable B2B-grade probiotic raw material solution for supplement brands, functional food companies, and health nutrition manufacturers worldwide.
About SugaRite™ and Bioyitech
SugaRite™ (ZC-SUGII) is a proprietary compound lactic acid bacteria premix developed by Bioyitech for metabolic health applications.
Bioyitech specializes in providing:
- B2B probiotic raw materials
- Customized probiotic formulations
- OEM/ODM probiotic solutions
- Functional nutrition ingredient services
Through scientific research and probiotic innovation, Bioyitech supports global partners in developing next-generation solutions for digestive health, metabolic wellness, and functional nutrition markets.
Explore SugaRite™ Probiotic Premix Solution
Discover more about SugaRite™ compound lactic acid bacteria powder and its applications in metabolic health product development.
Explore SugaRite™ Product Page
Disclaimer
The clinical outcomes described in this article are based on a specific 90-day human dietary intervention study involving individuals with type 2 diabetes mellitus.
SugaRite™ is a dietary supplement ingredient and not a pharmaceutical product. It is not intended to diagnose, treat, cure, or prevent diabetes or any other disease.
Individual responses may vary. Individuals managing diabetes should continue following professional medical advice and should not modify prescribed treatments without consulting healthcare professionals.